2023
DOI: 10.1016/j.jtocrr.2023.100532
|View full text |Cite
|
Sign up to set email alerts
|

Predictive Value of Combined Positive Score and Tumor Proportion Score for Immunotherapy Response in Advanced NSCLC

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
6
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 8 publications
(6 citation statements)
references
References 22 publications
(30 reference statements)
0
6
0
Order By: Relevance
“…Standard therapy for sarcoma with doxorubicin alone or doxorubicin + ifosfamide could not be administered due to the patient’s poor general condition. A high CPS has been associated with response to immune checkpoint inhibitors (ICIs) in several cancers[ 16 - 18 ], and the CPS was greater than 10 in the present case, and a response to ICI therapy was expected. However, the disease progressed rapidly, and the patient died before a response to ICI therapy could be obtained.…”
Section: Discussionmentioning
confidence: 61%
“…Standard therapy for sarcoma with doxorubicin alone or doxorubicin + ifosfamide could not be administered due to the patient’s poor general condition. A high CPS has been associated with response to immune checkpoint inhibitors (ICIs) in several cancers[ 16 - 18 ], and the CPS was greater than 10 in the present case, and a response to ICI therapy was expected. However, the disease progressed rapidly, and the patient died before a response to ICI therapy could be obtained.…”
Section: Discussionmentioning
confidence: 61%
“…The study of advanced NSCLC that evaluated PD-L1 expression in 187 cases found that PD-L1 TPS ≥ 1% was in 59.9% cases, while PD-L1 CPS ≥ 1% was in 72.2% cases. Furthermore, in 23 cases CPS was positive despite negative TPS score [ 45 ]. Moreover, when evaluating PD-L1 expression in 4459 advanced NSCLC cases, both TC and IC were considered, revealing predominant PD-L1 expression on immune cells.…”
Section: Discussionmentioning
confidence: 99%
“…In contrast to that in NSCLC, PD-L1 expression in other cancers such as head and neck squamous cell carcinoma is scored using the combined positive score (CPS), which encompasses PD-L1 expression on both tumor cells and immune cells in the tumor microenvironment [ 25 ]. Ulas et al reported that CPS differentiated overall survival better than TPS in patients with advanced NSCLC who received ICI monotherapy [ 26 ]. However, it is not clear whether CPS is a better predictive biomarker than TPS in NSCLC because of limited availability of related reports.…”
Section: Discussionmentioning
confidence: 99%